BIOMAT Database Logo BIOMAT Database Logo

Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis. 1995

D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Sandoz Laboratories Rueil Malmaison, France.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Comparison of neoral and sandimmun cyclosporines for de novo lung transplantation in cystic fibrosis patients.
June 1998, Transplantation proceedings,
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Bioavailability of Sandimmun® versus Sandimmun Neoral®: a meta-analysis of published studies.
January 2010, International journal of immunopathology and pharmacology,
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Use of Sandimmun Neoral in renal transplant patients. International Sandimmun Neoral Study Group.
October 1994, Transplantation proceedings,
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
January 1994, Transplant international : official journal of the European Society for Organ Transplantation,
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
An investigation of the pharmacokinetics, toxicity, and clinical efficacy of Neoral cyclosporin in cystic fibrosis patients.
January 1997, Transplantation proceedings,
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Microemulsion formulation increases cyclosporin bioavailability in cystic fibrosis.
December 1995, Lancet (London, England),
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients.
June 1997, Pediatric nephrology (Berlin, Germany),
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
January 1997, Transplantation proceedings,
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Sandimmun neoral, a new oral formulation of cyclosporin A with improved pharmacokinetic characteristics: safety and tolerability in renal transplant patients.
December 1994, Transplantation proceedings,
D Girault, and A Haloun, and L Viard, and G Bellon, and F Gottrand, and R Guillemain, and G Lenoir, and F L Ladurie, and E Plouvier, and V Storni
Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral.
January 1997, Annals of transplantation,
Copied contents to your clipboard!